Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for PURE Bioscience (PURE : OTCBB)

• Company Description    PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of `green` products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. Number of Employees: 11

• Price / Volume Information    Yesterday's Closing Price: $0.19 Daily Weekly Monthly 20 Day Moving Average: 22,839 shares Shares Outstanding: 88.02 (millions) Market Capitalization: $16.99 (millions) Beta: -0.02 52 Week High: $0.55 52 Week Low: $0.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.49% 16.54% 12 Week -3.50% 6.08% Year To Date 1.21% 21.80%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9669 HERMOSA AVENUE - RANCHO CUCAMONGA,CA 91730 USA ph: 619-596-8600 fax: 619-596-8790 melliott@purebio.com http://www.purebio.com

• General Corporate Information    Officers Tom Y. Lee - Chief Executive Officer Ivan Chen - Chairman of the Board Mark S. Elliott - Vice President; Finance Principal Financial and Ac Tom Myers - Director Kristin Taylor - Director Peer Information PURE Bioscience (BJCT) PURE Bioscience (CADMQ) PURE Bioscience (APNO) PURE Bioscience (UPDC) PURE Bioscience (IMTIQ) PURE Bioscience (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 74621T209 SIC: 2890 Fiscal Year Fiscal Year End: July Last Reported Quarter: 01/01/22 Next Expected EPS Date: 06/21/22 Share - Related Items Shares Outstanding: 88.02 Most Recent Split Date: 8.00 (0.13:1) Beta: -0.02 Market Capitalization: $16.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/21/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.69 Price/Cash Flow: - Price / Sales: 7.27 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -54.59% vs. Previous Quarter: -16.97% ROE 04/30/22 - - 01/31/22 - -107.81 10/31/21 - -81.11 ROA 04/30/22 - - 01/31/22 - -84.71 10/31/21 - -65.26 Current Ratio 04/30/22 - - 01/31/22 - 2.98 10/31/21 - 2.96 Quick Ratio 04/30/22 - - 01/31/22 - 2.47 10/31/21 - 2.59 Operating Margin 04/30/22 - - 01/31/22 - -140.39 10/31/21 - -103.45 Net Margin 04/30/22 - - 01/31/22 - -130.17 10/31/21 - -103.45 Pre-Tax Margin 04/30/22 - - 01/31/22 - -130.17 10/31/21 - -103.45 Book Value 04/30/22 - - 01/31/22 - 0.03 10/31/21 - 0.03 Inventory Turnover 04/30/22 - - 01/31/22 - 3.18 10/31/21 - 3.02 Debt-to-Equity 04/30/22 - - 01/31/22 - 0.00 10/31/21 - 0.00 Debt-to-Capital 04/30/22 - - 01/31/22 - 0.00 10/31/21 - 0.00

Powered by Zacks Investment Research ©